Subject: AIDS Drug in Clinical Trials Is Cleared for Limited Access
Date: Published: 10/6/92 (26 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Technology Brief -- Bristol-Myers Squibb Co.:
    AIDS Drug in Clinical Trials
    Is Cleared for Limited Access

    Bristol-Myers Squibb Co. said it received approval to open up
 access to an experimental AIDS drug, under a new Food and Drug
 Administration program.
    The drug, d4T or stavudine, is the first drug approved under the
 Parallel Track Program, established earlier this year to provide
 earlier access to new drugs still in clinical trials to people with
 life-threatening illnesses.  Usually, such drugs are only available
 to people participating in the clinical trials.
    Through the d4T program, AIDS patients may be eligible to receive
 the drug if they are intolerant of or failing on the two drugs
 approved for AIDS treatment -- Wellcome PLC unit Burroughs Wellcome
 Co. 's AZT (zidovudine) and Bristol-Myers's Videx (didanosine, or
 DDI).  Qualified patients will receive d4T at no charge through their
 physicians.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]